Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2026 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned...
February 25, 2026 07:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25,...
February 23, 2026 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile

HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous...
February 09, 2026 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim...
December 09, 2025 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical...
November 10, 2025 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with...
November 10, 2025 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an...
November 07, 2025 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: ...
November 06, 2025 08:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20

First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with...
November 06, 2025 08:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria...